Immucell (ICCC) Common Equity (2010 - 2026)

Immucell (ICCC) has reported Common Equity for 17 consecutive years, with $31.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 5.05% year-over-year to $31.4 million; the trailing twelve-month figure through Jun 2026 stood at $31.4 million (up 5.05% YoY), and the FY2025 full-year result was $27.1 million, down 1.68% from the prior year.
• Common Equity climbed to $31.4 million in Q2 2026 per ICCC's latest filing, from $27.1 million in the prior quarter.
• Across five years, Common Equity topped out at $33.2 million in Q1 2022 and bottomed at $23.5 million in Q2 2024.
• Historically, Common Equity has averaged $28.4 million across 5 years, with a median of $28.2 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Common Equity fell 18.66% in 2023, then rose 27.34% in 2025.
• Over 5 years, Common Equity stood at $30.4 million in 2022, then declined by 17.73% to $25.0 million in 2023, then gained by 10.1% to $27.5 million in 2024, then retreated by 1.68% to $27.1 million in 2025, then rose by 15.96% to $31.4 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $31.4 million, $27.1 million, and $29.8 million for Q2 2026, Q4 2025, and Q3 2025 respectively.